(R)-4-(tert-Butyl)-2-(6-phenylpyridin-2-yl)-4,5-dihydrooxazole, 97%, 10g

Thalidomide-O-amido-PEG3-C2-NH2 (TFA), 1g

tert-Butyl (1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclobutyl)carbamate, 95.0%, 25g

ROTI®Mount, 500 ml

Dichloroacetaldehyde diethyl acetal, 95%, 25g

(S)-(+)-Dihydro-5-(hydroxymethyl)furanone, 95.0%, 25g

Pyrrolidin-2-ylphosphonic acid hydrochloride, 70%, 250mg

2-Phosphobutane-1,2,4-tricarboxylic acid, (PBTC), min. 47%, 100 ml, glass packaging

N,N'-(Hexane-1,6-diyl)bis(3-phenylprop-2-en-1-imine)>98.0%(HPLC)(T)25g

(R)-4-(4-((3-amino-2-hydroxypropyl)amino)phenyl)morpholin-3-one (dihydrochloride), 98%, 50mg

5-Quinoxalinol>98.0%(GC)(T)1g

Methyl 2-chloro-6-(hydroxymethyl)nicotinate, 95%, 100mg

Sodium chloride >99%, 99.0%, 10kg